Imaging scan to guide surgery for medullary thyroid cancer
Tests a PET scan to help plan surgery for medullary thyroid cancer.
Plain-language title generated from the registry record
Registry title: 68Ga-TCR-FAPI PET/CT Guided Precision Surgery for MTC
Key facts
- Where
- Beijing, ChinaSee the site
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 75 years old?
Source: NCT06277180, who can take part
Where in China
- National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical CollegeBeijing, ChinaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- Trial code
- NCT06277180
- Record updated
- 26 February 2024
- Original description
This is a phase II clinical trial to evaluate the capability of 68Ga-labeled targeted covalent radiopharmaceutical (TCR) fibroblast activation protein inhibitor (FAPI) PET/CT to guide the surgical treatment of medullary thyroid carcinoma (MTC). The surgical extent of MTC is determined based on the lesion range revealed by 68Ga-TCR-FAPI PET/CT, with the main endpoint being 1-month post-surgical calcitonin level.Read full original descriptionShow less
Evaluating the Clinical Value of 68Ga-TCR-FAPI PET/CT to Guide the Surgical Treatment for Medullary Thyroid Carcinoma (MTC)
This is a phase II clinical trial to evaluate the capability of 68Ga-labeled targeted covalent radiopharmaceutical (TCR) fibroblast activation protein inhibitor (FAPI) PET/CT to guide the surgical treatment of medullary thyroid carcinoma (MTC). The surgical extent of MTC is determined based on the lesion range revealed by 68Ga-TCR-FAPI PET/CT, with the main endpoint being 1-month post-surgical calcitonin level.
Inclusion: Age between 18 and 75 years；; Diagnosed with MTC and have surgical indication based on preliminary evaluation; the tumor may be newly diagnosed or previously treated; Expected survival of at least 12 weeks; No major organ dysfunction (heart, lung, liver, kidney and other major organ include), acute or life-threatening status of infection; Be willing and able to understand the research content and provide written informed consent/assent for the trial.
Exclusion: Have a history of imaging agent allergies; No surgical indication (i.e., no measurable disease, unresectable disease, or significant present of distant metastasis), refusing surgery or 68Ga-TCR-FAPI PET/CT-guided surgery; Does not meet the PET-CT scan sedation requirements, or has contraindications for PET-CT examination; Be pregnant or breastfeeding, or expecting to conceive or father children within the projected duration of the trial.